{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363670319024315264.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1053/jhep.2003.50148"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1053%2Fjhep.2003.50148"}},{"identifier":{"@type":"URI","@value":"https://journals.lww.com/01515467-200304000-00008"}},{"identifier":{"@type":"NAID","@value":"30015126714"}}],"dc:title":[{"@value":"Long–Term Suppression of Hepatitis B E Antigen–Negative Chronic Hepatitis B by 24–Month Interferon Therapy"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:sec>\n            <jats:title/>\n            <jats:p>To assess whether extended treatment with interferon improves the outcome of hepatitis B e antigen (HBeAg)–negative chronic hepatitis B, 101 consecutive patients were treated with 6 MU of interferon alfa 2b 3 times weekly for 24 months. During the 68–month study, 30 patients (30%) had a sustained response (<jats:italic toggle=\"yes\">i.e.</jats:italic>, normal serum transaminase levels and undetectable hepatitis B virus DNA by non–polymerase chain reaction [PCR] assays), and 15 cleared serum surface antigen. Twenty–five nonresponders, 16 relapsers, and 30 who discontinued treatment were considered treatment failures. Multivariate analysis predicted a sustained response for young age (odds ratio, 0.94; 95% confidence interval, 0.89–0.99; <jats:italic toggle=\"yes\">P</jats:italic> = .041) and high pretreatment serum levels of immunoglobulin M (IgM) anti–hepatitis B core antigen (HBc) (odds ratio, 4.52; 95% confidence interval, 1.63–12.5; <jats:italic toggle=\"yes\">P</jats:italic> = .004). Liver disease progressed in none of the sustained responders but in 16 with treatment failure (0% vs. 22%, <jats:italic toggle=\"yes\">P</jats:italic> = .002); hepatocellular carcinoma (HCC) developed with similar frequency in both groups (7%). Overall, estimated 8–year complication–free survival was longer for the 30 sustained responders than the 71 patients with treatment failure (90% vs. 60%, <jats:italic toggle=\"yes\">P</jats:italic> < .001), but 8–year patient survival was similar in the 2 groups (100% and 90%). Short complication–free survival was predicted by failure to respond to interferon (hazard ratio, 7.8; 95% confidence interval, 1.8–34.0; <jats:italic toggle=\"yes\">P</jats:italic> = .006) and high scores for liver fibrosis (hazard ratio, 1.71; 95% confidence interval, 1.17–2.50; <jats:italic toggle=\"yes\">P</jats:italic> = .005). In conclusion, 24 months of treatment with interferon alfa 2b led to sustained disease suppression in a significant proportion of patients with HBeAg–negative chronic hepatitis B. (Hepatology 2003;37:756–763.)</jats:p>\n          </jats:sec>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380020700488863492","@type":"Researcher","foaf:name":[{"@value":"Pietro Lampertico"}]},{"@id":"https://cir.nii.ac.jp/crid/1380020700488863493","@type":"Researcher","foaf:name":[{"@value":"Ersilio Del Ninno"}]},{"@id":"https://cir.nii.ac.jp/crid/1380020700488863490","@type":"Researcher","foaf:name":[{"@value":"Mauro Viganò"}]},{"@id":"https://cir.nii.ac.jp/crid/1380020700488863489","@type":"Researcher","foaf:name":[{"@value":"Raffaella Romeo"}]},{"@id":"https://cir.nii.ac.jp/crid/1380020700488863488","@type":"Researcher","foaf:name":[{"@value":"Maria Francesca Donato"}]},{"@id":"https://cir.nii.ac.jp/crid/1380020700488863494","@type":"Researcher","foaf:name":[{"@value":"Erwin Sablon"}]},{"@id":"https://cir.nii.ac.jp/crid/1380020700488863491","@type":"Researcher","foaf:name":[{"@value":"Alberto Morabito"}]},{"@id":"https://cir.nii.ac.jp/crid/1380020700488863495","@type":"Researcher","foaf:name":[{"@value":"Massimo Colombo"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"02709139"}],"prism:publicationName":[{"@value":"Hepatology"}],"dc:publisher":[{"@value":"Ovid Technologies (Wolters Kluwer Health)"}],"prism:publicationDate":"2003-04","prism:volume":"37","prism:number":"4","prism:startingPage":"756","prism:endingPage":"763"},"reviewed":"false","dc:rights":["http://doi.wiley.com/10.1002/tdm_license_1.1"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1053%2Fjhep.2003.50148"},{"@id":"https://journals.lww.com/01515467-200304000-00008"}],"createdAt":"2003-04-07","modifiedAt":"2024-12-01","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004235757163264","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848664425007744","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Serum miRNAs Predicting Sustained HBs Antigen Reduction 48 Weeks after Pegylated Interferon Therapy in HBe Antigen-Negative Patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360857593780121984","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Association analysis of KIR/HLA genotype with liver cirrhosis, hepatocellular carcinoma, and NUC freedom in chronic hepatitis B patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360857593811432832","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Are Humanized Mouse Models Useful for Basic Research of Hepatocarcinogenesis through Chronic Hepatitis B Virus Infection?"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204792984064","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"日本肝臓学会コンセンサス神戸2009：C型肝炎の診断と治療"},{"@language":"en","@value":"JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis C"},{"@language":"ja-Kana","@value":"ニホン カンゾウ ガッカイ コンセンサス コウベ 2009 Cガタ カンエン ノ シンダン ト チリョウ"},{"@value":"日本肝臓学会コンセンサス神戸2009--B型肝炎の診断と治療"},{"@language":"ja-Kana","@value":"ニホン カンゾウ ガッカイ コンセンサス コウベ 2009 Bガタ カンエン ノ シンダン ト チリョウ"},{"@value":"JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001206399733120","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"B型肝炎ウイルスに対する治療の進歩"},{"@language":"en","@value":"The progress of antiviral therapy for chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1572543024932307584","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1573387450568547968","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1574231875093741440","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1053/jhep.2003.50148"},{"@type":"CIA","@value":"30015126714"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2010.00739.x_references_DOI_AO1YfVNQ9uYL4EvJNphPzsBYCpQ"},{"@type":"CROSSREF","@value":"10.2957/kanzo.51.243_references_DOI_AO1YfVNQ9uYL4EvJNphPzsBYCpQ"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_AO1YfVNQ9uYL4EvJNphPzsBYCpQ"},{"@type":"CROSSREF","@value":"10.3390/ijms19071940_references_DOI_AO1YfVNQ9uYL4EvJNphPzsBYCpQ"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_AO1YfVNQ9uYL4EvJNphPzsBYCpQ"},{"@type":"CROSSREF","@value":"10.1038/s41598-021-01014-x_references_DOI_AO1YfVNQ9uYL4EvJNphPzsBYCpQ"},{"@type":"CROSSREF","@value":"10.3390/v13101920_references_DOI_AO1YfVNQ9uYL4EvJNphPzsBYCpQ"}]}